Loading data for NEO — first visit, this takes a few seconds.
NeoGenomics Inc. (NEO)
NasdaqCM: NEO
· Real-Time Price · USD
16.41
-0.57 (-3.36%)
At close: Aug 24, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
NeoGenomics Inc. (NEO) Stock Price, Analysis & Data
-3.36% (1D)
No data available
| Bid | 11.97 |
| Market Cap | 2.11B |
| Revenue (ttm) | 766.29M |
| Net Income (ttm) | -51.88M |
| 1.73 | |
| -0.38 | |
| n/a | |
| 47.75 | |
| P/B (ttm) | 2.67 |
| P/S (ttm) | 2.79 |
| Earnings Date | Apr 29, 2025 |
| Ask | 20.49 |
| Volume | 1,093,873 |
| Avg. Volume (20D) | 2,796,361 |
| Open | 16.75 |
| Previous Close | 16.98 |
| Day's Range | 16.28 - 16.80 |
| 52-Week Range | 6.41 - 17.08 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Mar 16, 2004
Employees 2,500
Stock Exchange NasdaqCM
Ticker Symbol NEO
Website https://www.neogenomics.com
Financial Performance
In 2025, NeoGenomics's revenue was 727.33M, an increase of 10.11% compared to the previous year's 660.57M. Earnings were -108.03M, an increase of 37.22%.
Financial StatementsEarnings Surprise
NeoGenomics has released their quarterly earnings on Jul 28, 2026:
- Revenue of $201.66M misses estimates by $0, with 11.21% YoY growth.
- EPS of 0.05 exceeds estimates by 0.02, with 66.67% YoY growth.
NeoGenomics Inc. is scheduled to release its earnings on Apr 29, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2